You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-CD20 monoclonal antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Primary Immune Thrombocytopenia (ITP) Trial in Tianjin (TPO-RAs, TPO-RAs combining anti-CD 20 mAb)

Not yet recruiting
  • Primary Immune Thrombocytopenia (ITP)
  • TPO-RAs
  • TPO-RAs combining anti-CD 20 monoclonal antibody
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Feb 7, 2023

Primary Membranous Nephropathy Trial in Beijing (B007)

Not yet recruiting
  • Primary Membranous Nephropathy
  • Beijing, China
    Peking university first hospital
Dec 20, 2022

Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)

Not yet recruiting
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
Sep 20, 2023

Chronic Lymphocytic Leukemia Trial in Portland (drug, procedure, biological, other)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jul 12, 2023

Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma Trial in Duarte

Not yet recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +2 more
  • Biopsy
  • +8 more
  • Duarte, California
    City of Hope Medical Center
May 15, 2023

Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 20, 2022

Richter Syndrome, Chronic Lymphocytic Leukemia Trial in New York (Polatuzumab Vedotin, Rituximab, Etoposide)

Recruiting
  • Richter Syndrome
  • Chronic Lymphocytic Leukemia
  • Polatuzumab Vedotin
  • +5 more
  • New York, New York
    Weill Cornell Medicine
Dec 19, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 2, 2022

CD20-positive B-cell Non-Hodgkin Lymphoma Trial in Beijing (Recombinant anti-CD20 mAb-MMAE coupling agent for injection

Recruiting
  • CD20-positive B-cell Non-Hodgkin Lymphoma
  • Recombinant anti-CD20 monoclonal antibody-MMAE coupling agent for injection (TRS005)
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences, Cancer Hospital
May 24, 2022

Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

Completed
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 14, 2022

CD20 Positive B Cell Non-Hodgkin's Lymphoma Trial in Guangzhou, Tianjin (B001)

Completed
  • CD20 Positive B Cell Non-Hodgkin's Lymphoma
  • B001
  • Guangzhou, Guangdong, China
  • +1 more
Nov 11, 2021

Autoimmune Hemolytic Anemia, Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia Trial in Beijing (combination of a

Recruiting
  • Autoimmune Hemolytic Anemia
  • Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia
  • combination of a single dose anti-CD20 antibody and bortezomib
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 12, 2021

B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)

Not yet recruiting
  • B-cell Non-Hodgkins Lymphoma (B-NHL)
  • (no location specified)
Jan 5, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Scottsdale, Jacksonville, Rochester (drug, other, biological)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Scottsdale, Arizona
  • +2 more
Jan 5, 2023

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 17, 2022

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in

Recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +5 more
  • Fresno, California
  • +2 more
Jan 24, 2023

Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Refractory Nodular

Not yet recruiting
  • Nodular Lymphocyte Predominant Hodgkin Lymphoma
  • +2 more
  • Biopsy
  • +9 more
  • (no location specified)
Jun 1, 2023

Moderately to Severely Active Rheumatoid Arthritis Trial in Jiujiang (HLX01, Methotrexate(MTX))

Completed
  • Moderately to Severely Active Rheumatoid Arthritis
  • Jiujiang, Jiangxi, China
    Jiujiang No.1 peoples's hospital
May 4, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Portland (Ibrutinib, Obinutuzumab)

Completed
Has Results
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 10, 2021

Immune Thrombocytopenia, Treatment Trial in Tianjin (Obinutuzumab Injection [Gazyva])

Not yet recruiting
  • Immune Thrombocytopenia
  • Treatment
  • Obinutuzumab Injection [Gazyva]
  • Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
Aug 9, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Cyclophosphamide, Fludarabine Phosphate, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 5, 2023

Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder Trial

Not yet recruiting
  • Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
  • Polymorphic Post-Transplant Lymphoproliferative Disorder
  • Biopsy
  • +5 more
  • New Brunswick, New Jersey
  • +2 more
Mar 23, 2023

Immune Thrombocytopenia, Treatment Trial in Tianjin (Obinutuzumab Injection [Gazyva])

Not yet recruiting
  • Immune Thrombocytopenia
  • Treatment
  • Obinutuzumab Injection [Gazyva]
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Oct 17, 2023